Skip to content

The Effect of Supera Stents on Femoral and Popliteal Lesions under the

The Effect of Supera Stents on Femoral and Popliteal Lesions under the

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070093
Enrollment
Unknown
Registered
2023-04-01
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerotic obliterans

Interventions

group1 (active vascular preparation strategy):None

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (a) Symptomatic femoropopliteal artery disease (Rutherford 3-6) involving the distal superficial femoral artery (exit of the adductor canal) in patients older than 18 years; (b) Lesion length greater than 50mm but less than 250mm, diameter stenosis >50% or complete occlusion; (c) The guidewire can be successfully passed through the lesion and into the true lumen of the distal artery; (d) Infrapopliteal artery outflow tract > 1; (e) Use "aggressive vascular preparation strategy", that is, adequate proportional balloon dilatation, or volume reduction means; (f) Implantation of Supera stent in femoropopliteal artery lesion.

Exclusion criteria

Exclusion criteria: (a) patients with a life expectancy of less than one year; (b) the primary lesion becomes restenosis or reocclusion; (c) Patients with severe renal insufficiency such as uremia or iodine contrast medium allergy; (d) Patients intolerant to dual antiplatelet drug therapy.

Design outcomes

Primary

MeasureTime frame
Proportion of stents reaching the nominal release standard immediately after surgery;

Secondary

MeasureTime frame
One-year clinically driven target lesion reintervention rate;one-year primary patency rate of the stent;

Countries

China

Contacts

Public ContactGuo Daqiao
guo.daqiao@hotmail.com+86 13162372147

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026